Air 2, LLC dba VaporEFX
Tobacco ManufacturingColorado, United States11-50 Employees
ABOUT R2 INNOVATIONS THE COMPANY R2 Innovations, LLC was founded by Robert L. Senter and Robert E. Matuszewski in 1998 a privately owned, Colorado Limited Liability Company. R2 has arranged equity partnerships with industry leaders in the field of drying and micronizing microparticles and nanoparticles into dry powder aerosols for the purpose of inhalation therapies, targeting the treatment of respiratory diseases, including asthma, emphysema and COPD. In addition to dry powder formulations targeting pulmonary and respiratory disorders; US patent pending processes, research and studies are underway to convert CBD, cannabidiol and other cannabis derived, extracted oils into pharmaceutical grade, fine powder formulations using R2’s pressurized, metered dose inhaler (pMDI) and R2's dry powder inhaler (DPI) technologies directed at treating stress, post traumatic stress disorders (PTSD), anti-inflammatory pain relief and insomnia. R2 MISSION R2’s Mission is to be recognized as a global leader in the development and manufacturing of natural medicines to treat specific, targeted ailments and diseases. At R2 we are devoted to delivering alternative medical treatments to solve ongoing medical problems and support important advancements in medical science. R2 OBJECTIVE R2’s objective is to challenge the use of; fluticasone propionate/salmeterol xinafoate, budesonide/formoterol, albuterol/salbutamol, budesonide, fluticasone and formoterol fumarate as the preferred corticosteroid medical treatments in existing metered dose inhalers eliminating adverse side effects, and the threat of death with overdosing for asthmatic, COPD and Emphysema patients. R2 VISION R2's Vision is to lead the global marketplace in advanced alternative medicines with an emphasis on respiratory therapies, supported by clinical research, double blind studies and independent lab testing.
1-888-653-2347 
support@leadiq.com 
